TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.95
−1.71%0
Insider buys (3m)
2
Insider sells (3m)
-$317.8K
Net value (3m)
-15.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Heffernan Michael Thomas · director | Sale | 20,952 | $15 |
| Sep 17, 2026 | Heffernan Michael Thomas · director | M-Exempt | 18,421 | $3.04 |
| Sep 17, 2026 | Heffernan Michael Thomas · director | M-Exempt | 21,052 | $3.33 |
| Sep 17, 2026 | Heffernan Michael Thomas · director | Sale | 100 | $16 |
| Jun 4, 2026 | Heffernan Michael Thomas · director | A-Award | 35,000 | $13 |
| Jun 4, 2026 | Meeker David P · director | A-Award | 35,000 | $13 |
| Jun 4, 2026 | Colangelo Dominick · director | A-Award | 35,000 | $13 |
| Jun 4, 2026 | Mathers Edward T · director | A-Award | 35,000 | $13 |
| Jun 4, 2026 | VANLENT ANNE · director | A-Award | 35,000 | $13 |
| Feb 20, 2026 | SCIASCIA THOMAS · officer: Chief Scientific Officer | A-Award | 85,000 | $11 |
| Feb 20, 2026 | Cassella James V · officer: Chief Development Officer | A-Award | 215,000 | $11 |
| Feb 20, 2026 | GOOD JENNIFER L · director, officer: President & CEO | A-Award | 675,000 | $11 |
| Feb 20, 2026 | Simon Farrell · officer: Chief Commercial Officer | A-Award | 160,000 | $11 |
| Feb 20, 2026 | Galletta Christopher · officer: See Remarks | A-Award | 35,000 | $11 |
| Jan 12, 2026 | HASTINGS DAVID C · officer: Chief Financial Officer | A-Award | 375,000 | $11 |
| Dec 3, 2025 | Galletta Christopher · officer: See Remarks | M-Exempt | 4,225 | $0.51 |
| Jun 13, 2025 | VANLENT ANNE · director | A-Award | 45,000 | $6.25 |
| Jun 13, 2025 | Mathers Edward T · director | A-Award | 45,000 | $6.25 |
| Jun 13, 2025 | Colangelo Dominick · director | A-Award | 45,000 | $6.25 |
| Jun 13, 2025 | Heffernan Michael Thomas · director | A-Award | 45,000 | $6.25 |
| Jun 13, 2025 | Meeker David P · director | A-Award | 45,000 | $6.25 |
| Jun 3, 2025 | Galletta Christopher · officer: See Remarks | A-Award | 8,550 | $2.38 |
| Jun 3, 2025 | SCIASCIA THOMAS · officer: Chief Scientific Officer | A-Award | 60,000 | $2.38 |
| Jun 3, 2025 | Delfini Lisa · officer: Chief Financial Officer | A-Award | 72,000 | $2.38 |
| Jun 3, 2025 | Simon Farrell · officer: Chief Commercial Officer | A-Award | 72,000 | $2.38 |
| Jun 3, 2025 | GOOD JENNIFER L · director, officer: President & CEO | A-Award | 102,000 | $2.38 |
| Mar 26, 2025 | SCIASCIA THOMAS · officer: Chief Scientific Officer | Sale | 2,631 | $6.60 |
| Mar 26, 2025 | SCIASCIA THOMAS · officer: Chief Scientific Officer | M-Exempt | 2,631 | $1.43 |
| Mar 25, 2025 | GOOD JENNIFER L · director, officer: President & CEO | M-Exempt | 5,263 | $1.43 |
| Mar 25, 2025 | GOOD JENNIFER L · director, officer: President & CEO | Sale | 5,263 | $6.58 |
Institutional positioning
13F filings over the trailing two quarters
New 85Increased 156Reduced 125Sold out 19
| Filer | Action | Shares | Filed |
|---|---|---|---|
| NEA Management Company, LLC | Unchanged | 13,222,228 | Aug 14, 2026 |
| NEA MANAGEMENT COMPANY, LLC | Unchanged | 13,222,228 | May 15, 2026 |
| FMR LLC | Increased | 12,562,839 | Aug 13, 2026 |
| BlackRock, Inc. | Increased | 11,155,026 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 10,240,186 | May 13, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Reduced | 9,939,547 | May 15, 2026 |
| Frazier Life Sciences Management, L.P. | Reduced | 9,939,447 | Aug 14, 2026 |
| FMR LLC | Increased | 8,038,061 | May 15, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 5,684,592 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 5,530,675 | Aug 13, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 5,189,088 | May 15, 2026 |
| VIVO CAPITAL, LLC | Unchanged | 5,094,668 | May 20, 2026 |
| Vivo Capital, LLC | Unchanged | 5,094,668 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 4,978,567 | May 15, 2026 |
| Woodline Partners LP | Increased | 4,081,333 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 17, 2026